I'm thrilled to be speaking with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research and development has positioned him at the forefront of cutting-edge cancer treatment technologies. Today, we’ll dive into the groundbreaking work on nanodots made from molybdenum
After first-line therapy fails in advanced biliary cancer, the next decision can stretch between hope for extra months and fear of heavy toxicity, a fraught balance that now places FOLFIRINOX squarely under the spotlight. Clinics see this crossroads every week: a patient who just progressed on
In operating rooms where silence often amplifies stress, a small change—a pair of headphones and a vigilant recovery plan—can shift the arc of the first hours after colorectal cancer surgery, easing the path from anesthesia to wakefulness while trimming complications that make families and
When a lifesaving transplant risks unleashing the very immune fire meant to cure leukemia, choices about how to steer immunity before donor cells arrive determine whether patients heal or face harm. That dilemma sits at the heart of allogeneic hematopoietic stem cell transplantation, where
Jan Kaiserle sits down with Ivan Kairatov, a biopharma expert deeply versed in molecular therapeutics and translational research, to discuss a new approach to overcoming treatment resistance in neuroblastoma. Drawing on work published in Science Advances in 2025, Kairatov explains how a failed
If bacteria aren’t the whole story of the tumor microenvironment, what crucial signals are being missed from fungi that quietly occupy the same space yet account for only a sliver of the sequencing reads but a disproportionate share of immune cues and clinical outcomes? That challenge has gained
